Immune Durability After VSV-EBOV Vaccination

Status Completed

Clinical Trial Summary

This prospective observational cohort study will follow the roughly 100 adults who received the VSV-ZEBOV vaccine in the Geneva phase 1 randomized controlled trial in 2014-2015 in order to determine their long-term (5-year) immune response to vaccination.

Clinical Trial Description

Background: During the Ebola epidemic of 2014-5, there was no proven therapy or prevention available beyond horizontal infection control measures. After the Canadian government donated 800 vials of the vaccine candidate VSV-EBOV to World Health Organization (WHO), the University Hospitals of Geneva agreed to perform a WHO-coordinated phase I/II double-blind, placebo-controlled randomized trial to assess the candidate's safety and immunogenicity healthy adult volunteers. The doses of 10 E7 pfu and 5 x 10 E7 pfu were tested in 35 and 16 volunteers, respectively, before a safety-driven study hold in late 2014. At trial resumption in early 2015, the remaining volunteers (n=51) received 3 x 10 E5 pfu. Thirteen volunteers received placebo. Among vaccinees, early immune responses were impressive, even at the lowest dose of 3 x 10 E5 pfu, and persisted well up to 6 months (last time point assessed). The trial successfully ended 12 months after injection. This prospective observational study will assess immune durability in this group of vaccinees at yearly time points up to five years post-vaccination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02933931
Study type	Observational
Source	University Hospital, Geneva
Contact
Status	Completed
Phase
Start date	November 2016
Completion date	January 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05009251` - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake	N/A
Completed	`NCT03284515` - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Completed	`NCT05012163` - Lottery Incentive Nudges to Increase Influenza Vaccinations	N/A
Recruiting	`NCT05996549` - Cost-effectiveness of the Influenza Vaccination	Phase 4
Completed	`NCT04323137` - Encouraging Flu Vaccination Among High-Risk Patients Identified by ML	N/A
Completed	`NCT01224301` - School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities	N/A
Completed	`NCT00169858` - Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections	Phase 4
Completed	`NCT05509283` - Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications	N/A
Completed	`NCT02907580` - Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric	N/A
Recruiting	`NCT06160999` - Improving Uptake of Pediatric Vaccines Through Religious Conferences and Vaccines-in-a-van in Aceh, Indonesia	N/A
Recruiting	`NCT03875703` - Post-Vaccination Biological Collection
Completed	`NCT03287830` - Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine	N/A
Completed	`NCT02907645` - Influenza Vaccine Randomized Educational Trial: Adult	N/A
Completed	`NCT03220555` - Efficacy of the Buzzy® Device on the Prevention of Health Care Induced Pediatric Pain in a Vaccination Center	N/A
Withdrawn	`NCT05023512` - Understanding Public Attitudes Towards the COVID-19 Vaccination	N/A
Recruiting	`NCT02937428` - To Look or Not to Look at the Needle During Vaccination	Phase 3
Completed	`NCT00813319` - Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females	Phase 3
Completed	`NCT03104790` - Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls	Phase 4
Completed	`NCT04780867` - Psychological and Lifestyle Factors on Health Outcomes	N/A
Completed	`NCT03239795` - Promoting Influenza Vaccination In General Practice Waiting Rooms	N/A